Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Synthesis and Functional Evaluation of Novel Aldose Reductase Inhibitors

By Bentham Science Publishers | April 25, 2017

Diabetes mellitus (DM) is probably one of the oldest known diseases and the incidence has been increasing steadily all over the world. This metabolic disease is characterized by chronic hyperglycemia due to defect in insulin secretion and/or insulin action. The etiopathology is very complex and is closely related with long-term damage, dysfunction, and failure of various organs, such as the eyes, kidneys, nerves, heart, and blood vessels.

Strong epidemiological evidence suggest a relationship between blood sugar levels and the onset of diabetes complications, in fact, excess glucose in the body leads to conversion of sugar into its corresponding alcohol, namely sorbitol, via the polyol pathway. The activation of this pathway is dependent on the enzyme aldose reductase (ARL2) and thus its inhibition should be prevented or delay the onset of both micro- and macrovascular complications such as retinopathy, peripheral vascular disease and coronary artery disease.

Currently, only the carboxylic acid epalrestat, an aldose reductase inhibitor (ARI), is available on the market and used for the treatment of diabetic neuropathy in Japan, India and China.

Many ARIs have shown to be clinically unsuccessful because of adverse pharmacokinetics or toxic side-effects.

In this study, we described the design, synthesis and biological evaluation of three small series of spirobenzopyran acetic acid derivatives, proposed as a scaffold for novel ALR2 inhibitors. Most of the new ARIs proved to inhibit the target enzyme, showing IC50 values in the micromolar/low micromolar range, without affecting the activity of another important enzyme, namely ARL1, which plays a detoxifying role in metabolic processes involved in the physiological homeostasis.

These results suggested that the spirobenzopyran scaffold represents a new and promising tool that could pave the way to the discovery of novel and effective ARIs.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE